Stockscreener 앱 받기
110.04
8.92%
-10.78
시간 외 거래:
111.89
1.85
+1.68%
전일 마감가:
$120.82
열려 있는:
$116.48
하루 거래량:
2.17M
Relative Volume:
2.41
시가총액:
$6.68B
수익:
$3.99B
순이익/손실:
$463.16M
주가수익비율:
15.50
EPS:
7.1
순현금흐름:
$1.10B
1주 성능:
-10.48%
1개월 성능:
-20.81%
6개월 성능:
+0.60%
1년 성능:
-4.49%
1일 변동 폭
$109.76
$117.11
1주일 범위
$109.76
$127.87
52주 변동 폭
$99.06
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
110.04 | 6.68B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Potential Tariffs Pose Challenges for Jazz Pharmaceuticals (JAZZ) - GuruFocus
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating - MarketScreener
Post-traumatic Stress Disorder Treatment Market Generated - openPR.com
After a year of 4.3% returns, Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) share price drop last week may have less of an impact on institutional investors - Yahoo Finance
JAZZ or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teacher Retirement System of Texas Buys 2,346 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - Eagle-Tribune
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Jazz Pharma Reveals Growth Strategy: Key Updates Coming at Major Healthcare Conference - Stock Titan
Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Axsome's ADHD drug meets main goal in late-stage study - Marketscreener.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Jazz strikes the chord with $935m Chimerix acquisition - Xconomy
Based On Its ROE, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A High Quality Stock? - simplywall.st
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride - Yahoo Finance
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - GlobeNewswire Inc.
Akari Therapeutics Appoints Biotechnology Industry Leader, - GlobeNewswire
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Yahoo Finance
Interesting JAZZ Put And Call Options For October 17th - Nasdaq
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? - Yahoo Finance
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting - PR Newswire
Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears - Law360
JAZZ or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition? - Yahoo Finance
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Yahoo Finance
Jazz Pharmaceuticals EVP sells shares worth $332,604 By Investing.com - Investing.com South Africa
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant - Yahoo Finance
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Bull of the Day: Jazz Pharmaceuticals (JAZZ) - Yahoo Finance
Insider Sell: Bruce Cozadd Sells 6,500 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus.com
Bull Of The Day: Jazz Pharmaceuticals (JAZZ) - Barchart
H.C. Wainwright lifts Jazz stock target to $217, maintains Buy By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga India
Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group - Defense World
Robert Iannone Sells 7,080 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock - Defense World
Morgan Stanley Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00 - Defense World
UBS Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145 - Marketscreener.com
UBS raises Jazz Pharmaceuticals stock rating to Buy, target to $179 By Investing.com - Investing.com UK
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):